Expression of miR-17-5p showed an increase (p<0.001) in both subcutaneous and visceral T2DM ASCs, whereas expression of miR-140-5p was downregulated after treating subcutaneous and visceral T2DM ASCs (p<0.001 and p<0.01, respectively) with bFGF for 9 days (Fig. 2a). Here, FGF2 is linked to type 2 diabetes mellitus.